No Prescription |
 |
 | ||
|
Syndopa 110 Sinemet |
|
| ||
No Prescription » Prescription Drugs 15 » Syndopa 110 Sinemet Syndopa is indicated in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans) post-encephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Buy Syndopa 110 Sinemet and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Syndopa 110 Sinemet: Product Type: Prescription Drugs 15 Syndopa 110 (Sinemet Generic Carbidopa/Levodopa) Syndopa 110 (Sinemet Generic Carbidopa/Levodopa) Sinemet Generic Carbidopa/Levodopa 10/100mg Sinemet Generic Carbidopa/Levodopa Syndopa 110
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
